Immunochina Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 266

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 30

Immunochina Pharmaceuticals General Information

Description

Developer of cell and gene therapies designed to treat malignant hematological diseases, solid tumors, and autoimmune disorders. The company utilizes proprietary technology platforms to develop autologous and allogeneic CAR-T drug candidates, enabling healthcare providers to offer advanced treatment options for conditions such as refractory non-Hodgkin lymphoma, colorectal cancer, and systemic lupus erythematosus.

Contact Information

Formerly Known As
Beijing Yimiao Shenzhou Medical Technology Co., Ltd
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 101, 1st Floor, Building 54
  • No. 2 Yuquan Road, Haidian District
  • Beijing, 100089
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 101, 1st Floor, Building 54
  • No. 2 Yuquan Road, Haidian District
  • Beijing, 100089
  • China
+86 010

Immunochina Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunochina Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. IPO 30-Jun-2026 Announced Generating Revenue
13. Secondary Transaction - Private 01-Feb-2026 Completed Generating Revenue
12. Secondary Transaction - Private 01-Mar-2025 Completed Generating Revenue
11. Later Stage VC (Series E) 09-Jan-2025 Completed Generating Revenue
10. Secondary Transaction - Private 01-Jul-2023 Completed Generating Revenue
9. Later Stage VC (Series D1) 01-Nov-2022 Completed Generating Revenue
8. Later Stage VC (Series D) 24-Nov-2021 Completed Generating Revenue
7. Later Stage VC (Series C2) 22-Dec-2020 Completed Generating Revenue
6. Later Stage VC (Series C1) 25-Sep-2020 $14.6M $45.1M Completed Generating Revenue
5. Later Stage VC (Series C) 22-Jan-2019 $20.5M $30.4M Completed Generating Revenue
To view Immunochina Pharmaceuticals’s complete valuation and funding history, request access »

Immunochina Pharmaceuticals Patents

Immunochina Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022143870-A1 Antibody that specifically binds to bcma and application thereof Inactive 31-Dec-2020
EP-4265638-A1 Chimeric antigen receptor targeting cd123 and use thereof Pending 16-Dec-2020
EP-4265638-A4 Chimeric antigen receptor targeting cd123 and use thereof Pending 16-Dec-2020
WO-2022127401-A1 Chimeric antigen receptor targeting cd123 and use thereof Inactive 16-Dec-2020
WO-2022121899-A1 Antibody specifically binding to strep-tag ii tag and use thereof Inactive 08-Dec-2020 C07K16/1292
To view Immunochina Pharmaceuticals’s complete patent history, request access »

Immunochina Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunochina Pharmaceuticals Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Haiguorongzhi Private Equity Fund Management Corporate Venture Capital Minority
Hosencare Brothers Growth/Expansion Minority
China Development Bank Capital Fund of Funds Minority
State Development and Investment Group Government Minority
SUNNOVO Corporation Minority
You’re viewing 5 of 30 investors. Get the full list »

Immunochina Pharmaceuticals FAQs

  • When was Immunochina Pharmaceuticals founded?

    Immunochina Pharmaceuticals was founded in 2015.

  • Where is Immunochina Pharmaceuticals headquartered?

    Immunochina Pharmaceuticals is headquartered in Beijing, China.

  • What is the size of Immunochina Pharmaceuticals?

    Immunochina Pharmaceuticals has 266 total employees.

  • What industry is Immunochina Pharmaceuticals in?

    Immunochina Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Immunochina Pharmaceuticals a private or public company?

    Immunochina Pharmaceuticals is a Private company.

  • What is Immunochina Pharmaceuticals’s current revenue?

    The current revenue for Immunochina Pharmaceuticals is .

  • How much funding has Immunochina Pharmaceuticals raised over time?

    Immunochina Pharmaceuticals has raised $99M.

  • Who are Immunochina Pharmaceuticals’s investors?

    Beijing Haiguorongzhi Private Equity Fund Management, Hosencare Brothers, China Development Bank Capital, State Development and Investment Group, and SUNNOVO are 5 of 30 investors who have invested in Immunochina Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process